IRCCS Istituto Nazionale Tumori Fondazione Pascale

27 trials 17 recruiting Academic / non-commercial

Filter these 27 trials by condition, phase, country and more.

Open in Search →

27 Registered trials

17 Recruiting

5 Completed trials

2 Countries active

43 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 3 Phase II/III: 2 Phase II: 19 Phase I/II: 1 Phase I: 1 Phase I (Other): 1

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Colorectal cancer metastatic 4 Ovarian cancer recurrent 2 ARID1A gene mutation 1 Lung cancer metastatic 1 Ovarian cancer 1 Rectal cancer 1 Gastrooesophageal cancer 1 Prostate cancer 1 Oropharyngeal cancer 1 Pancreatic carcinoma 1 Cholangiocarcinoma 1 Oral neoplasm 1

Top IMPs

OXALIPLATIN 4 FLUOROURACIL 3 IRINOTECAN HYDROCHLORIDE TRIHYDRATE 3 OLAPARIB 3 BLEOMYCIN SULFATE 2 CALCIUM LEVOFOLINATE 2 CISPLATIN 2 LENVATINIB 2 PACLITAXEL ALBUMIN-BOUND 2 PANITUMUMAB 2 AFLIBERCEPT 1 BEVACIZUMAB 1

All trials — page 2

27 total

MILES5 – A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC Ended

2024-515326-83-00 Phase II 1 country
BEVERLY: A randomized open-label phase 3 trial comparing bevacizumab + erlotinib vs erlotinib alone as first line treatment of patients with… Ended

2024-516843-15-00 Phase III 1 country
Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlle… Ended

2025-520735-16-00 Phase II 1 country BLEOMYCIN SULFATE; CARBOPLATIN; CISPLATIN; FLUOROURACIL

Showing 25–27 of 27 trials

← All sponsors A–Z